EUVIMEDEUVIMED entdecken
Kohortenstudie

Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

Shiori Hishida-Sadaka, Hirotoshi Iihara, Koichi Ohata, Serika Matsuoka, Daichi Watanabe, Takuji Iwashita, Shinya Uemura, Masahito Shimizu, Akio Suzuki

Supportive Care in Cancer · 2023

DOI: 10.1007/s00520-023-08136-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Supportive Care in Cancer, 2023. Verfasst von Shiori Hishida-Sadaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan. Hauptthemen laut MEDLINE: Antiemetics, Pancreatic Neoplasms, Hyperglycemia, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Modified FOLFIRINOX (mFFX), a standard chemotherapy regimen for advanced pancreatic cancer (APC), is expected to be associated with a higher risk of chemotherapy-induced nausea and vomiting (CINV). Herein, we conducted a retrospective cohort study to evaluate the efficacy and safety of a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of CINV during mFFX therapy. METHODS: This study enrolled patients with APC who received mFFX as initial therapy with a combination of 5HT3RA, DEX, and NK1RA as antiemetic prophylaxis. The primary endpoint was the complete response (CR) rate during cycle 1, which was defined as no emetic episodes and no rescue medication use during the overall period (0-120 h). Safety was also evaluated with a focus on hyperglycemia, which is a concern in patients with APC. RESULTS: Seventy patients were eligible for this retrospective analysis. The CR rate during the overall period was 51.4%. Significant nausea, defined as grade 2 or higher, peaked to 77.1% on days 4-5, but remained above 65% until day 7. Hyperglycemia occurred in 37.1% of patients, and 34.3% were grade 3 hyperglycemia. CONCLUSIONS: CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days. Enhanced antiemetic measures for mFFX are desirable. However, in patients with diabetes mellitus complications, sparing of steroids and glycemic control should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsPancreatic NeoplasmsHyperglycemiaAntineoplastic AgentsHumansNeurokinin-1 Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesDexamethasoneVomitingNauseaLeucovorinFluorouracilIrinotecanOxaliplatin

Stichwörter der Autor:innen

Advanced pancreatic cancerAntiemetic therapyChemotherapyChemotherapy-induced nausea and vomiting

Substanzen

AntiemeticsNeurokinin-1 Receptor AntagonistsDexamethasoneAntineoplastic AgentsfolfirinoxLeucovorinFluorouracilIrinotecanOxaliplatin

Autor:innen und Institutionen

  • Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
  • Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan. iihara.hirotoshi.p7@f.gifu-u.ac.jp.
  • Patient Safety Division, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan. iihara.hirotoshi.p7@f.gifu-u.ac.jp.
  • Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, Gifu, 501-1196, Japan. iihara.hirotoshi.p7@f.gifu-u.ac.jp.
  • Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
  • Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, Gifu, 501-1196, Japan.

Zitieren

APA

Hishida-Sadaka, S., Iihara, H., Ohata, K., Matsuoka, S., Watanabe, D., Iwashita, T., Uemura, S., Shimizu, M., & Suzuki, A. (2023). Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-023-08136-0

Vancouver

Hishida-Sadaka S, Iihara H, Ohata K, Matsuoka S, Watanabe D, Iwashita T, et al. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study. Supportive Care in Cancer. 2023. doi:10.1007/s00520-023-08136-0

BibTeX
@article{HishidaSadaka2023,
  author = {Hishida-Sadaka, Shiori and Iihara, Hirotoshi and Ohata, Koichi and Matsuoka, Serika and Watanabe, Daichi and Iwashita, Takuji and Uemura, Shinya and Shimizu, Masahito and Suzuki, Akio},
  title = {Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study},
  journal = {Supportive Care in Cancer},
  year = {2023},
  doi = {10.1007/s00520-023-08136-0}
}
Kostenlos starten →